Compare Ascendis Pharma A/S (ASND) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs United States Natural Gas Fund — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while United States Natural Gas Fund trades at $10.38. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals.
| ASND | UNG | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Commodities - Energy |
52-Week High | $277.18 | $16.90 |
52-Week Low | $163.32 | $10.15 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
UNG (United States Natural Gas Fund) trades at $10.60, down 2.12% amid bearish technical signals with 17 sell indicators versus 3 buy signals. The ETF faces headwinds from natural gas price volatility, though RSI levels near 30 suggest potential oversold conditions. Recent news highlights weather-driven demand fluctuations and structural challenges including contango effects that have historically eroded long-term returns.
Outlook remains cautious given the fund's tracking of futures contracts rather than company fundamentals. Key risks include weather dependency and LNG export volatility, while oversold technical conditions may offer short-term trading opportunities for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
